Breast cancer in the young

The age of genomic profiling

Identifying BRCA mutations for breast and ovarian cancer

HER2CLIMB: Investigating tucatinib with capecitabine and trastuzumab in HER2-positive metastatic breast cancer

Oral paclitaxel yields better outcomes than IV paclitaxel in metastatic breast cancer

Selective oestrogen receptor degraders as treatment for ER positive/HER2 negative advanced/metastatic breast cancer

The challenges of treating breast cancer in Brazil

The importance of central pathology pCR review in an international multicenter neoadjuvant study in HER2 positive early BC

SABCS 2019 highlights

The PEARL study: Palbociclib and endocrine therapy vs capecitabine in HR /HER2- metastatic breast cancer

Imaging for women who are high risk of breast cancer

Exploring adjuvant endocrine therapy use with letrozole in postmenopausal women with hormone receptor-positive breast cancer